Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Complication Prevention in Complex AF and VT Procedures
Author(s): Pasquale Santangeli , Dhanunjaya Lakkireddy Added: 4 hours ago
Dr Dhanunjaya Lakkireddy (Kansas City Heart Rhythm Institute, Kansas City, US) and Dr Pasquale Santangeli (Cleveland Clinic, Cleveland, OH, US) discuss evidence-based strategies for preventing complications during complex atrial fibrillation and ventricular tachycardia ablation procedures.This expert discussion focuses on safety considerations in high-risk electrophysiology procedures, comparing… View more

Electrophysiology & Arrhythmia
Selecting NOAC to Optimise Stroke Prevention in AF – Part 1
Author(s): Tri Huynh Quang Ho , Minh That Ton , Viet Lan Nguyen , et al Added: 2 years ago

Anticoagulation

Electrophysiology & Arrhythmia
ADA 25: PATHWEIGH: Weight Management in Primary Care
Author(s): Leigh Perreault Added: 7 months ago
ADA 25 - PATHWEIGH roadmap for implementing weight management into primary care eliminated a population weight gain trajectory.Dr Leigh Perreault (University of Colorado Anschutz Medical Campus, US) joins us remotely to discuss the PATHWEIGH trial, which investigated a process of care to facilitate and prioritize weight management in a primary care setting. PATHWEIGH focused on reducing excess… View more

Cardiovascular Renal Metabolic
TCT 25: Short-Term Anticoagulation Vs DAPT for Preventing Device Thrombosis Following LAAC
Author(s): Josep Rodés-Cabau Added: 3 months ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device… View more

Anticoagulation

Imaging & Diagnostics
Prevention: What's New at HFA 2025?
Author(s): Harriette Van Spall , Maja Cikes Added: 8 months ago
ESC HF 25 - Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Maja Cikes (University Hospital Centre Zagreb, HR) for an insightful wrap up of the novel data concerning preventive cardiology that was presented at 2025's Heart Failure Congress.Trials discussed include:REDICAE (00:42)FINEARTS HF (02:27)CRISPR Gene Editing with Nexiguran Ziclumeran (05:53)HELIOS B (07:12)RESHAPE… View more

Heart Failure
Selecting NOAC to Optimise Stroke Prevention in AF – Part 2
Author(s): Minh That Ton , Tri Huynh Quang Ho , Viet Lan Nguyen , et al Added: 2 years ago

Anticoagulation

Electrophysiology & Arrhythmia
AHA 23: Preventive Cardiology in 2023
Author(s): Michael Honigberg Added: 2 years ago
AHA 23 — Dr Michael Honigberg (Massachusetts General Hospital, US) highlights key 2023 cardiology updates, featuring novel data from AHA Scientific Sessions.Dr Honigberg provides commentary on the new SELECT trial outcomes and emphasises the incretin mimetic, semaglutide's role in cardiovascular medicine. He delves into lipid management with a focus on the CLEAR trial data and the incorporation… View more

Guidelines & Statements

Prevention & Chronic Conditions
ESC 25: The HI-PRO Trial
Author(s): Gregory Piazza Added: 5 months ago
ESC Congress 2025 - HI-PRO shows apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism when compared to placebo at 12 months.Dr Gregory Piazza (Brigham and Women's Hospital, US) joins us to discuss findings from the HI-PRO trial, evaluating extended-duration low-intensity apixaban versus placebo for secondary prevention in high-risk patients with provoked… View more

Anticoagulation

Vascular Disease and Surgery
The Future of Heart Failure With Dr Yancy
Author(s): Clyde W Yancy Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Clyde Yancy (Northwestern University, US) joins us to explore the future trajectory of heart failure management, examining how prevention strategies, precision medicine approaches, and the evolving responsibilities of cardiologists are reshaping patient outcomes.Interview Questions:Looking at the current state of heart failure management, what do you see as the… View more

Guidelines & Statements

Heart Failure
HFSA 24: The EMBARK HFpEF Trial
Author(s): Added: 1 year ago
HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892).EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.Interview Questions:What is the… View more

Heart Failure